Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Acadia Healthcare Company, Inc. stock logo
ACHC
Acadia Healthcare
$37.59
-0.9%
$31.04
$11.43
▼
$39.70
$3.53B0.642.55 million shs1.69 million shs
Neurogene Inc. stock logo
NGNE
Neurogene
$23.14
+0.2%
$27.31
$15.93
▼
$43.66
$478.19M1.75297,722 shs247,169 shs
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
$3.99
-0.3%
$4.43
$3.45
▼
$7.30
$1.30B1.362.89 million shs3.55 million shs
The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Acadia Healthcare Company, Inc. stock logo
ACHC
Acadia Healthcare
-1.96%-1.81%+26.55%+38.67%+142.43%
Neurogene Inc. stock logo
NGNE
Neurogene
-0.86%-8.62%-0.65%-41.42%+2.85%
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
-1.48%-6.54%+10.50%-37.79%-2.91%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Acadia Healthcare Company, Inc. stock logo
ACHC
Acadia Healthcare
$37.59
-0.9%
$31.04
$11.43
▼
$39.70
$3.53B0.642.55 million shs1.69 million shs
Neurogene Inc. stock logo
NGNE
Neurogene
$23.14
+0.2%
$27.31
$15.93
▼
$43.66
$478.19M1.75297,722 shs247,169 shs
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
$3.99
-0.3%
$4.43
$3.45
▼
$7.30
$1.30B1.362.89 million shs3.55 million shs
The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Acadia Healthcare Company, Inc. stock logo
ACHC
Acadia Healthcare
-1.96%-1.81%+26.55%+38.67%+142.43%
Neurogene Inc. stock logo
NGNE
Neurogene
-0.86%-8.62%-0.65%-41.42%+2.85%
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
-1.48%-6.54%+10.50%-37.79%-2.91%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Acadia Healthcare Company, Inc. stock logo
ACHC
Acadia Healthcare
2.53
Moderate Buy$32.54-13.44% Downside
Neurogene Inc. stock logo
NGNE
Neurogene
3.00
Buy$79.57243.87% Upside
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
3.00
Buy$12.75219.55% Upside

Current Analyst Ratings Breakdown

Latest ACHC, NGNE, and TSHA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/10/2026
Neurogene Inc. stock logo
NGNE
Neurogene
Lower Price TargetBuy$65.00 ➝ $60.00
11/9/2026
Acadia Healthcare Company, Inc. stock logo
ACHC
Acadia Healthcare
UpgradeHold ➝ Strong-Buy
11/6/2026
Acadia Healthcare Company, Inc. stock logo
ACHC
Acadia Healthcare
Boost Price TargetOutperform$31.00 ➝ $41.00
11/6/2026
Acadia Healthcare Company, Inc. stock logo
ACHC
Acadia Healthcare
Boost Price TargetBuy$39.00 ➝ $41.00
11/6/2026
Acadia Healthcare Company, Inc. stock logo
ACHC
Acadia Healthcare
Boost Price TargetNeutral$30.00 ➝ $39.00
11/5/2026
Acadia Healthcare Company, Inc. stock logo
ACHC
Acadia Healthcare
Boost Price TargetEqual Weight$32.00 ➝ $35.00
11/4/2026
Acadia Healthcare Company, Inc. stock logo
ACHC
Acadia Healthcare
Initiated CoverageModerate Buy
10/28/2026
Neurogene Inc. stock logo
NGNE
Neurogene
Reiterated RatingBuy$65.00
10/15/2026
Neurogene Inc. stock logo
NGNE
Neurogene
Reiterated RatingSell (D-)
10/8/2026
Neurogene Inc. stock logo
NGNE
Neurogene
Initiated CoverageOverweight$60.00
10/6/2026
Acadia Healthcare Company, Inc. stock logo
ACHC
Acadia Healthcare
Reiterated RatingNeutral
(Data available from 11/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Acadia Healthcare Company, Inc. stock logo
ACHC
Acadia Healthcare
$3.31B1.05$4.05 per share9.29$21.75 per share1.73
Neurogene Inc. stock logo
NGNE
Neurogene
$930K515.05N/AN/A$17.14 per share1.35
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
$9.77M133.16N/AN/A$1.09 per share3.66
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Acadia Healthcare Company, Inc. stock logo
ACHC
Acadia Healthcare
-$1.10B-$12.47N/A19.284.76-33.07%6.53%2.33%N/A
Neurogene Inc. stock logo
NGNE
Neurogene
-$90.35M-$5.09N/AN/AN/AN/A-44.36%-40.61%N/A
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
-$109M-$0.43N/AN/AN/AN/A-51.87%-40.29%N/A

Latest ACHC, NGNE, and TSHA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/12/2026Q3 2026
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
-$0.1286-$0.10+$0.0286-$0.10$0.76 millionN/A
11/9/2026Q3 2026
Neurogene Inc. stock logo
NGNE
Neurogene
-$1.36-$1.05+$0.31-$1.05N/AN/A
11/4/2026Q3 2026
Acadia Healthcare Company, Inc. stock logo
ACHC
Acadia Healthcare
$0.4625$0.60+$0.1375$0.38$877.76 million$895.31 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Acadia Healthcare Company, Inc. stock logo
ACHC
Acadia Healthcare
N/AN/AN/AN/AN/A
Neurogene Inc. stock logo
NGNE
Neurogene
N/AN/AN/AN/AN/A
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Acadia Healthcare Company, Inc. stock logo
ACHC
Acadia Healthcare
1.15
1.60
1.60
Neurogene Inc. stock logo
NGNE
Neurogene
N/A
19.97
19.97
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
0.13
18.56
18.56

Institutional Ownership

CompanyInstitutional Ownership
Acadia Healthcare Company, Inc. stock logo
ACHC
Acadia Healthcare
N/A
Neurogene Inc. stock logo
NGNE
Neurogene
52.37%
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
77.70%

Insider Ownership

CompanyInsider Ownership
Acadia Healthcare Company, Inc. stock logo
ACHC
Acadia Healthcare
1.20%
Neurogene Inc. stock logo
NGNE
Neurogene
11.68%
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
3.48%
CompanyEmployeesShares OutstandingFree FloatOptionable
Acadia Healthcare Company, Inc. stock logo
ACHC
Acadia Healthcare
25,00092.97 million91.85 millionOptionable
Neurogene Inc. stock logo
NGNE
Neurogene
13120.70 million18.28 millionOptionable
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
99326.05 million314.70 millionOptionable

Recent News About These Companies

Taysha Gene Therapies (NASDAQ:TSHA) Upgraded at Wall Street Zen
Taysha (TSHA) Q3 2026 Earnings Call Transcript
Taysha Gene Therapies Q3 Earnings Call Highlights
Taysha Gene Therapies' Q3 Net Loss Widens
Taysha Gene Therapies Q3 2026 earnings preview
Taysha Gene Therapies (TSHA) Stock Looks Rich Against Book Value

New MarketBeat Followers Over Time

Media Sentiment Over Time

Acadia Healthcare stock logo

Acadia Healthcare NASDAQ:ACHC

$37.59 -0.35 (-0.92%)
Closing price 04:00 PM Eastern
Extended Trading
$37.72 +0.13 (+0.35%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Acadia Healthcare Company, Inc. provides behavioral healthcare services in the United States and Puerto Rico. The company develops and operates acute inpatient psychiatric facilities, specialty treatment facilities comprising residential recovery facilities and eating disorder facilities, comprehensive treatment centers, and residential treatment centers, as well as facilities offering outpatient behavioral healthcare services for the behavioral healthcare and recovery needs of communities. Acadia Healthcare Company, Inc. was founded in 2005 and is headquartered in Franklin, Tennessee.

Neurogene stock logo

Neurogene NASDAQ:NGNE

$23.14 +0.04 (+0.17%)
Closing price 04:00 PM Eastern
Extended Trading
$23.18 +0.04 (+0.19%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.

Taysha Gene Therapies stock logo

Taysha Gene Therapies NASDAQ:TSHA

$3.99 -0.01 (-0.25%)
Closing price 04:00 PM Eastern
Extended Trading
$4.00 +0.00 (+0.13%)
As of 05:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.